Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
MDRX

MDRX - Allscripts Healthcare Solutions Inc Stock Price, Fair Value and News

9.73USD-0.08 (-0.82%)Delayed

Market Summary

MDRX
USD9.73-0.08
Delayed
-0.82%

MDRX Stock Price

View Fullscreen

MDRX RSI Chart

MDRX Valuation

Market Cap

934.2M

Price/Earnings (Trailing)

15.41

Price/Sales (Trailing)

1.12

EV/EBITDA

2.14

Price/Free Cashflow

6.04

MDRX Price/Sales (Trailing)

MDRX Profitability

Free Cashflow Yield

16.56%

MDRX Fundamentals

MDRX Revenue

MDRX Earnings

Breaking Down MDRX Revenue

Last 7 days

0.5%

Last 30 days

3.1%

Last 90 days

30.3%

Trailing 12 Months

-25.7%

How does MDRX drawdown profile look like?

MDRX Financial Health

MDRX Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2022820.2M829.9M837.2M0
20211.3B1.0B805.9M811.2M
20201.6B1.6B1.5B1.5B
20191.7B1.7B1.7B1.6B
20181.6B1.7B1.7B1.7B
20171.5B1.5B1.5B1.5B
20161.4B1.4B1.5B1.5B
20151.4B1.4B1.4B1.4B
20141.4B1.4B1.4B1.4B
20131.4B1.4B1.4B1.4B
20121.5B1.5B1.5B1.4B
20111.1B1.3B1.4B1.4B
2010661.9M704.5M922.2M1.0B
20090534.0M576.6M619.3M
20080383.8M00

Tracking the Latest Insider Buys and Sells of Allscripts Healthcare Solutions Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 31, 2024
langan thomas
acquired
-
-
157,895
ceo
May 31, 2024
zierhoffer carol j
acquired
-
-
42,106
-
May 31, 2024
garrison greg
acquired
-
-
21,053
execuitive chairman
May 31, 2024
garrison greg
sold (taxes)
-58,700
9.5
-6,179
execuitive chairman
May 31, 2024
hammond lisa
acquired
-
-
52,632
svp & chief hr officer
May 31, 2024
westerfield leland
acquired
-
-
105,264
cfo
May 31, 2024
vakharia tejal
acquired
-
-
63,158
svp general counsel
May 31, 2024
rodriguez susan
acquired
-
-
42,106
-
May 31, 2024
altman elizabeth ann
acquired
-
-
42,106
-
May 31, 2024
judge jonathan
acquired
-
-
42,106
-

1–10 of 50

Which funds bought or sold MDRX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 17, 2024
Meadow Creek Wealth Advisors LLC
sold off
-100
-82,829
-
-%
Jul 10, 2024
CWM, LLC
sold off
-100
-6,000
-
-%
Jul 08, 2024
Versant Capital Management, Inc
sold off
-100
-308
-
-%
Jul 02, 2024
GAMMA Investing LLC
reduced
-7.54
445
3,610
-%
Jul 01, 2024
Legal & General Group Plc
sold off
-100
-3,300,570
-
-%
Jun 11, 2024
EverSource Wealth Advisors, LLC
sold off
-100
-1,532
-
-%
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
-132,000
245,000
-%
May 22, 2024
Livelsberger Financial Advisory
sold off
-100
-1,941
-
-%
May 22, 2024
BURNEY CO/
sold off
-100
-2,312,820
-
-%
May 20, 2024
Highlander Capital Management, LLC
unchanged
-
-4,883
13,475
-%

1–10 of 46

Are Funds Buying or Selling MDRX?

Are funds buying MDRX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own MDRX
No. of Funds

Unveiling Allscripts Healthcare Solutions Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 10, 2024
madison avenue partners, lp
5.7%
6,100,902
SC 13G
May 16, 2024
kent lake capital llc
5.00%
5,385,000
SC 13D
Apr 05, 2024
blackrock inc.
0.0%
7,625
SC 13G/A
Mar 12, 2024
kent lake capital llc
5.54%
6e+06
SC 13G
Mar 11, 2024
vanguard group inc
3.38%
3,697,374
SC 13G/A
Mar 08, 2024
newtyn management, llc
9.6%
10,500,000
SC 13G
Mar 07, 2024
blackrock inc.
9.5%
10,412,077
SC 13G/A
Mar 04, 2024
stonehill capital management llc
19.5%
21,141,983
SC 13G
Feb 13, 2024
vanguard group inc
13.07%
14,275,875
SC 13G/A
Feb 09, 2024
dimensional fund advisors lp
8.2%
8,977,642
SC 13G/A

Recent SEC filings of Allscripts Healthcare Solutions Inc

View All Filings
Date Filed Form Type Document
Jun 20, 2024
4
Insider Trading
Jun 20, 2024
4
Insider Trading
Jun 20, 2024
4
Insider Trading
Jun 20, 2024
4
Insider Trading
Jun 20, 2024
4
Insider Trading
Jun 20, 2024
4
Insider Trading
Jun 20, 2024
4
Insider Trading
Jun 20, 2024
4
Insider Trading
Jun 20, 2024
4
Insider Trading
Jun 20, 2024
4
Insider Trading

Peers (Alternatives to Allscripts Healthcare Solutions Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
519.5B
379.5B
17.33% 12.05%
33.82
1.37
12.96% -25.81%
96.7B
206.0B
1.72% 16.37%
25.1
0.47
12.55% -43.95%
84.2B
66.7B
-5.62% 12.14%
15.39
1.26
9.59% -4.59%
75.2B
360.9B
-1.82% -19.47%
10.26
0.21
9.07% 78.83%
35.1B
155.5B
-1.07% -4.10%
12.82
0.23
6.34% 84.42%
12.2B
14.7B
-4.81% 19.04%
14.94
0.83
7.99% 19.23%
11.9B
12.3B
-4.32% 29.88%
14.63
0.97
5.77% 58.74%
MID-CAP
8.2B
2.3B
1.82% -0.86%
28.92
3.57
5.96% 18.29%
6.2B
3.0B
-2.69% -11.33%
-545.53
2.06
10.92% -104.06%
2.7B
1.5B
17.05% 40.55%
43.86
1.88
19.34% 40.15%
2.1B
3.5B
6.32% -49.56%
14.73
0.61
-27.67% -62.40%
SMALL-CAP
2.0B
1.1B
0.03% 29.58%
29.72
1.79
11.45% 30.74%
1.5B
3.0B
16.04% 110.14%
-8.52
0.49
4.98% 4.88%
72.1M
-
21.59% -10.97%
-4.77
-
- -1.05%
20.1M
21.6M
-0.62% 19.10%
39.62
0.93
9.04% -57.88%

Allscripts Healthcare Solutions Inc News

Latest updates
PR Newswire3 months ago

Allscripts Healthcare Solutions Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q12017Q42017Q3
Revenue0.7%152151143392145141134386366369381414408411399442432441434436368
Cost Of Revenue-4.1%68.0071.0069.0066575.0073.0071.00225230232249262260252249254254268249260206
Gross Profit5.0%83.0079.0073.0041970.0068.0063.00161135138132153149159150188178174185176162
  S&GA Expenses-45.7%33.0060.0041.0022627.0028.0032.0094.0093.0011093.0010896.0010096.0010010812312012394.00
  R&D Expenses4.1%24.0023.0023.0013121.0021.0021.0054.0046.0046.0059.0060.0061.0062.0062.0066.0063.0074.0065.0068.0046.00
EBITDA Margin-3.2%0.36*0.37*0.42*0.43*0.12*0.09*0.06*0.05*0.06*0.06*-0.03*-0.02*---------
Interest Expenses-34.0%1.002.002.003.004.003.003.006.007.0010.0011.0012.0011.0010.0010.0014.0013.0012.0012.0012.009.00
Income Taxes261.7%14.00-8.58-14.4215.007.004.001.00-10.05-4.122.00-4.53-29.74-5.64-5.26-2.69-5.45-1.647.000.00-9.972.00
Earnings Before Taxes566.3%25.00-5.324.0099.0027.0030.005.00-74.75-18.07-19.57-36.92-63.60-25.39-168-23.96-40.04-13.7892.00-24.86-32.58-12.03
EBT Margin-3.0%0.15*0.15*0.20*0.20*-0.01*-0.06*-0.09*-0.10*-0.09*-0.09*-0.18*-0.17*---------
Net Income122.7%15.00-64.0323.0087.0016.0022.009.007281.00-7.60-20.35-18.97-5.72-149-7.98386-23.8574.00-28.5115.00-17.46
Net Income Margin-3.5%0.07*0.08*0.18*0.17*0.96*0.74*0.58*0.47*-0.03*-0.03*-0.12*-0.11*---------
Free Cashflow1048.9%28.00-2.9469.0061.0055.00-2004.00-18750.0021.00-6.489.00---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q12017Q42017Q3
Assets-1.4%1,6911,7142,4302,4252,4842,5402,8712,9183,1463,1893,2533,2063,2303,2353,2423,1814,5184,3544,3704,2303,883
  Current Assets-2.2%8118291,5417618058411,1351,153949870907841774804834859844856911857668
    Cash Equivalents-1.5%49350083.0013314216045453121919920413012913913717491.00114112131104
  Net PPE-21.8%12.0015.009.0010.0054.0059.0067.0072.0070.0076.0082.0088.0097.00106116122160161165135165
  Goodwill0.0%5245245205079749759759751,2871,3611,3619741,3871,3821,3749862,2081002,0511,29361.00
Liabilities-0.8%5145181,0771,0171,0661,1471,1931,2511,9381,9462,0111,9211,9491,9191,7861,6012,9332,7562,8162,6392,316
  Current Liabilities-1.3%2532566475475675968809357451,1111,1581,2111,177880800798894907889890684
  Long Term Debt0.2%2002003773503734211691681,0266626805515558237666481,0029831,064907747
    LT Debt, Current---------48.0037537136435922.0021.0020.0020.0020.0020.0028.0025.00
    LT Debt, Non Current0.2%2002003773503734211691681,0266626805515558237666481,0029831,064907747
Shareholder's Equity-1.6%1,1771,1961,3531,4081,4191,3931,6791,6661,2081,2431,2421,2851,2811,3161,4561,5801,1171,1421,1101,1601,105
  Retained Earnings2.0%75373980313.00680664642633-94.71-95.25-87.64-49.34-30.37-24.64125133-251-228-319-338-354
  Additional Paid-In Capital0.0%1,9241,9241,9221,9621,9521,9041,9071,9031,9291,9211,9151,9071,8761,8681,8581,8811,7651,7671,7711,7811,782
Shares Outstanding-1.4%109111115116123125141140158163162162---------
Minority Interest----------------29.0029.0029.0038.0039.0041.00
Float------2,252---1,079---1,894---2,056---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q12017Q42017Q3
Cashflow From Operations1821.2%28,141-1,63569,26165,04555,889-200,9374,575-178,62052,96722,646-3,70812,31035,854-7,7265,816-13,66315,0148,23258,308106,23263,824
  Share Based Compensation-49.5%4,5539,0246,32426,3653,9821,9812,8418,1058,8117,1669,9549,4197,77310,13211,6588,7718,7137,1979,9578,4009,679
Cashflow From Investing-101.4%-9,254657,172-44,19942,697-20,327-15,556-18,9891,680,120-24,226-6,277-34,429-30,771-52,766-44,109-33,410481,334-212,803129,294-149,812-206,161-104,896
Cashflow From Financing86.6%-38,454-285,954-62,966-133,546-50,080-67,726-7,514-1,190,025-9,499-23,678113,44316,9707,74352,146-9,516-402,371176,841-140,16672,713152,93961,182
  Buy Backs-64.1%33,65993,69349,679108,490-308,953-279,58145,568-9,7149,30037,090-65,07037,023-44,30657,599--
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

MDRX Income Statement

2022-09-30
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue:    
Revenue from contract with customers$ 151,922$ 144,668$ 445,492$ 419,526
Cost of revenue:    
Total cost of revenue68,48675,028209,093218,550
Gross profit83,43669,640236,399200,976
Selling, general and administrative expenses32,51827,392133,68387,680
Research and development23,68121,04269,85162,644
Asset impairment charges03590531
Amortization of intangible and acquisition-related assets2,2362,3636,6487,090
Income from operations25,00118,48426,21743,031
Interest expense(1,246)(3,617)(5,269)(9,709)
Other income, net1,6554,4933,80021,819
Gain on sale of businesses, net08,36308,363
Equity in net loss income of unconsolidated investments(617)(257)(1,222)(321)
Income from continuing operations before income taxes24,79327,46623,52663,183
Income tax (provision) benefit(13,868)(7,190)9,132(12,464)
Income from continuing operations, net of tax10,92520,27632,65850,719
Income (loss) from discontinued operations(434)(6,187)(9,252)(6,545)
Gain on sale of discontinued operations5,17407,939647
Income tax effect on discontinued operations(1,137)2,091(57,986)2,342
Income (loss) from discontinued operations, net of tax3,603(4,096)(59,299)(3,556)
Net income (loss)$ 14,528$ 16,180$ (26,641)$ 47,163
Basic    
Continuing operations$ 0.10$ 0.16$ 0.29$ 0.38
Discontinued operations0.03(0.03)(0.52)(0.03)
Net earnings (loss) per Common Share0.130.13(0.23)0.35
Diluted    
Continuing operations0.090.150.250.36
Discontinued operations0.03(0.03)(0.44)(0.03)
Net earnings (loss) per Common Share$ 0.12$ 0.12$ (0.19)$ 0.33
Provider [Member]    
Revenue:    
Revenue from contract with customers$ 122,811$ 118,179$ 360,415$ 345,253
Cost of revenue:    
Total cost of revenue57,25261,606172,595180,566
Payer & Life Sciences [Member]    
Revenue:    
Revenue from contract with customers29,11126,48985,07774,273
Cost of revenue:    
Total cost of revenue$ 11,234$ 13,422$ 36,498$ 37,984

MDRX Balance Sheet

2022-09-30
CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 492,597$ 132,517
Restricted cash1,3071,308
Accounts receivable, net of allowance of $12,868 and $13,360 as of September 30, 2022 and December 31, 2021, respectively169,029171,622
Contract assets, net of allowance of $564 and $576 as of September 30, 2022 and December 31, 2021, respectively65,45363,429
Prepaid expenses and other current assets74,38460,511
Assets held for sale8,000331,955
Total current assets attributable to discontinued operations810,770761,342
Fixed assets, net11,7139,819
Software development costs, net78,10374,688
Intangible assets, net145,255149,690
Goodwill523,927506,607
Deferred taxes, net60
Contract assets - long-term, net of allowance of $1,201 and $1,534 as of September 30, 2022 and December 31, 2021, respectively27,95728,174
Right-of-use assets - operating leases14,52018,324
Other assets78,40883,429
Long-term assets attributable to discontinued operations0793,156
Total assets1,690,6592,425,229
Current liabilities:  
Accounts payable12,6095,281
Accrued expenses82,91754,518
Accrued compensation and benefits33,85731,055
Deferred revenue98,930120,748
Current operating lease liabilities6,1666,133
Current liabilities attributable to discontinued operations18,612329,347
Total current liabilities attributable to discontinued operations253,091547,082
Long-term debt200,326350,062
Deferred revenue3,0601,839
Deferred taxes, net8,08216,625
Long-term operating lease liabilities12,31516,754
Other liabilities36,76233,823
Long-term liabilities attributable to discontinued operations050,906
Total liabilities513,6361,017,091
Commitments and contingencies
Stockholders’ equity:  
Preferred stock: $0.01 par value, 1,000 shares authorized, no shares issued and outstanding as of September 30, 2022 and December 31, 202100
Common stock: $0.01 par value, 349,000 shares authorized as of September 30, 2022 and December 31, 2021; 279,600 and 109,260 shares issued and outstanding as of September 30, 2022, respectively; 276,705 and 116,114 shares issued and outstanding as of December 31, 2021, respectively2,7942,766
Treasury stock: at cost, 170,340 and 160,591 shares as of September 30, 2022 and December 31, 2021, respectively(1,498,836)(1,321,805)
Additional paid-in capital1,923,5591,962,386
Retained earnings753,392767,556
Accumulated other comprehensive loss(3,886)(2,765)
Total stockholders’ equity1,177,0231,408,138
Total liabilities and stockholders’ equity$ 1,690,659$ 2,425,229
MDRX
Veradigm Inc., a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions. The company operates through two segments, Hospitals and Large Physician Practices, and Veradigm. The Hospitals and Large Physician Practices segment provides integrated clinical and financial management solutions, which primarily include EHR-related software; and related installation, support and maintenance, outsourcing, private cloud hosting, and revenue cycle management services. The Veradigm segment offers payer and life sciences solutions, which are primarily targeted at payers, life sciences companies, and other healthcare stakeholders; and software applications for patient engagement and EHR software to single-specialty, and small and mid-sized physician practices, including related clinical, financial, administrative, and operational solutions. Its solutions enable clients to transition, analyze, and coordinate care, and enhance the healthcare delivery across the care community. The company serves physicians, hospitals, governments and militaries, health systems, health plans, life-sciences companies, retail clinics, surgery centers, retail pharmacies, pharmacy benefit managers, insurance companies, employer wellness clinics, consumers, lab companies, urgent care facilities, and venture capital firms, as well as post-acute organizations, such as home health and hospice agencies. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.
 CEO
 WEBSITEhttps://veradigm.com
 INDUSTRYHealthcare Plans
 EMPLOYEES8000

Allscripts Healthcare Solutions Inc Frequently Asked Questions


What is the ticker symbol for Allscripts Healthcare Solutions Inc? What does MDRX stand for in stocks?

MDRX is the stock ticker symbol of Allscripts Healthcare Solutions Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Allscripts Healthcare Solutions Inc (MDRX)?

As of Thu Jul 18 2024, market cap of Allscripts Healthcare Solutions Inc is 934.17 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MDRX stock?

You can check MDRX's fair value in chart for subscribers.

What is the fair value of MDRX stock?

You can check MDRX's fair value in chart for subscribers. The fair value of Allscripts Healthcare Solutions Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Allscripts Healthcare Solutions Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MDRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Allscripts Healthcare Solutions Inc a good stock to buy?

The fair value guage provides a quick view whether MDRX is over valued or under valued. Whether Allscripts Healthcare Solutions Inc is cheap or expensive depends on the assumptions which impact Allscripts Healthcare Solutions Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MDRX.

What is Allscripts Healthcare Solutions Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 18 2024, MDRX's PE ratio (Price to Earnings) is 15.41 and Price to Sales (PS) ratio is 1.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MDRX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Allscripts Healthcare Solutions Inc's stock?

In the past 10 years, Allscripts Healthcare Solutions Inc has provided -0.051 (multiply by 100 for percentage) rate of return.